Tirzepatide has emerged as a groundbreaking treatment for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its access have become key issues for patients and healthcare practitioners. While tirzepatide has been approved by regulatory agencies, its high-priced nature presents a significant challenge to